Previous 10 | Next 10 |
Swiss pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) and clinical-stage biotech, Harpoon Therapeutics (NASDAQ:HARP) have entered into a clinical supply agreement for the delivery of Roche’s (OTCQX:RHHBY) cancer therapy atezolizumab (Tecentriq) in studies that Harpoon (HARP) expects to ...
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to sup...
Gainers: Avadel Pharmaceuticals (AVDL) +31%. AlloVir (ALVR) +7%. Redbox Entertainment (RDBX) +6%. CymaBay Therapeutics (CBAY) +5%. Harpoon Therapeutics. (HARP) +5%. Losers: Protagonist Therapeutics (PTGX) -41%. Nkarta (NKTX) -6%. Provention Bio (PRVB...
SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with preclinical data for its TriTAC-XR T cell engager platform at the American Associ...
The clinical-stage immunotherapy company, Harpoon Therapeutics (NASDAQ:HARP) is trading ~4% lower in the post-market Thursday after announcing the departure of its Chief Medical Officer, Natalie Sacks, effective June 01, 2022. However, Dr. Sacks will serve the company as a consultan...
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, ...
Harpoon Therapeutics Inc. (NASDAQ:HARP) traded at a new 52-week high today of $25.05. Approximately 10.9 million shares have changed hands today, as compared to an average 30-day volume of 503,000 shares. Over the past year, Harpoon Therapeutics Inc. has traded in a range of $3.30 to $24...
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncolo...
Several Street firms have lowered their price targets for Harpoon Therapeutics (HARP -10.9%) though are keeping either buy or overweight ratings. Shares are down 11% in late morning trading. Piper Sandler's Joseph Catanzaro lowered his target to $15 from $27 (~282% return based on F...
The clinical-stage immunotherapy company Harpoon Therapeutics (HARP -34.8%) have lost more than a third on Friday after announcing its plans to discontinue the clinical work on HPN424, an experimental therapy for prostate cancer. The decision followed “a careful and thorough analysis o...
News, Short Squeeze, Breakout and More Instantly...
Harpoon Therapeutics Inc. Company Name:
HARP Stock Symbol:
NASDAQ Market:
Harpoon Therapeutics Inc. Website:
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
2024-02-14 02:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-23 08:45:00 ET On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics , (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the first half of this year, is to gain access to Harpoon's t...